{"id":745192,"date":"2015-05-28T15:30:00","date_gmt":"2015-05-28T15:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\/"},"modified":"2025-11-07T01:25:11","modified_gmt":"2025-11-07T06:25:11","slug":"merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\/","title":{"rendered":"Merck Submits U.S. New Drug Application for Grazoprevir\/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection"},"content":{"rendered":"<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the company has submitted a New Drug Application to<br \/>\n      the U.S. Food and Drug Administration (FDA) for grazoprevir\/elbasvir<br \/>\n      (100mg\/50mg), an investigational once-daily, single tablet combination<br \/>\n      therapy for the treatment of adult patients with chronic hepatitis C<br \/>\n      genotypes (GT) 1, 4 or 6 infection. Within 60 days of submission, the<br \/>\n      FDA will determine whether it will accept for review Merck&#8217;s application<br \/>\n      as filed. The company plans to submit additional license applications in<br \/>\n      the European Union and other markets by the end of 2015.\n    <\/p>\n<p>\n      \u201cMerck&#8217;s submission is based on evidence from our wide-ranging clinical<br \/>\n      program assessing the efficacy and tolerability profile of<br \/>\n      grazoprevir\/elbasvir in populations with chronic hepatitis C,\u201d said Dr.<br \/>\n      Roy Baynes, senior vice president of clinical development, Merck<br \/>\n      Research Laboratories. \u201cThis submission to the U.S. FDA is an important<br \/>\n      milestone as we seek to provide patients with a new treatment option for<br \/>\n      this serious infection.\u201d\n    <\/p>\n<p>\n      The FDA has previously granted Breakthrough Therapy designation status<br \/>\n      for grazoprevir\/elbasvir for the treatment of patients infected with<br \/>\n      chronic HCV GT1 with end stage renal disease on hemodialysis, and for<br \/>\n      patients infected with chronic HCV GT4. Breakthrough Therapy designation<br \/>\n      is intended to expedite the development and review of a candidate that<br \/>\n      is planned for use, alone or in combination, to treat a serious or<br \/>\n      life-threatening disease or condition when preliminary clinical evidence<br \/>\n      indicates that the drug may demonstrate substantial improvement over<br \/>\n      existing therapies on one or more clinically significant endpoints.\n    <\/p>\n<p>\n      The New Drug Application for grazoprevir\/elbasvir (100mg\/50mg) is based<br \/>\n      in part upon data from the pivotal <i>C-EDGE<\/i>\u00a0clinical trials<br \/>\n      program, as well as the <i>C-SURFER<\/i> and <i>C-SALVAGE<\/i> trials,<br \/>\n      evaluating grazoprevir\/elbasvir (100mg\/50mg), with or without ribavirin,<br \/>\n      in patients with chronic hepatitis C infection. Data from these trials<br \/>\n      were presented at\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Filc-congress.eu%2F&amp;esheet=51112393&amp;newsitemid=20150528006341&amp;lan=en-US&amp;anchor=The+International+Liver+CongressTM+2015&amp;index=1&amp;md5=f8c7614474b8f485e5d548ff7bfd4c1e\" rel=\"nofollow\">The<br \/>\n      International Liver Congress<sup>TM <\/sup>2015<\/a> in April 2015.\n    <\/p>\n<p>\n      <b>About Grazoprevir\/Elbasvir<\/b>\n    <\/p>\n<p>\n      Grazoprevir\/elbasvir is an investigational, once-daily single tablet<br \/>\n      regimen consisting of grazoprevir (NS3\/4A protease inhibitor) and<br \/>\n      elbasvir (NS5A replication complex inhibitor). As part of Merck\u2019s broad<br \/>\n      clinical trials program, grazoprevir\/elbasvir is being studied in<br \/>\n      multiple HCV genotypes and in patients with difficult-to-treat<br \/>\n      conditions such as HIV\/HCV co-infection, advanced chronic kidney<br \/>\n      disease, inherited blood disorders, liver cirrhosis and those on opiate<br \/>\n      substitution therapy.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51112393&amp;newsitemid=20150528006341&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=3af7a21eae5ac1770e2b80bfdd2e3993\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51112393&amp;newsitemid=20150528006341&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=1a126deedc3f9694dae626c5dd23e105\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51112393&amp;newsitemid=20150528006341&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=81392cfc31c902d1b8e309d6d8a9aad7\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51112393&amp;newsitemid=20150528006341&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=ef44b94f892876e1436f3a449a4429c4\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the U.S. Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of Merck\u2019s management and are subject<br \/>\n      to significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise except as required by applicable law. Additional factors that<br \/>\n      could cause results to differ materially from those described in the<br \/>\n      forward-looking statements can be found in Merck\u2019s 2014 Annual Report on<br \/>\n      Form 10-K and the company\u2019s other filings with the Securities and<br \/>\n      Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51112393&amp;newsitemid=20150528006341&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=910d44a787ce13dade16da720eb62af2\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150528006341r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li, 908-246-5701<br \/>or<br \/>Sarra Herzog,        908-740-1871<br \/>or<br \/>Investors:<br \/>Joe Romanelli, 908-740-1986<br \/>or<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for grazoprevir\/elbasvir (100mg\/50mg), an investigational once-daily, single tablet combination therapy for the treatment of adult patients with chronic hepatitis C genotypes (GT) 1, 4 or 6 infection. Within 60 days of submission, the FDA will determine whether it will accept for review Merck&#8217;s application as filed. The company plans to submit additional license applications in the European Union and other markets by the end of 2015. \u201cMerck&#8217;s submission is based on evidence from our wide-ranging clinical program assessing the efficacy and tolerability profile of grazoprevir\/elbasvir in populations with chronic hepatitis C,\u201d said Dr. Roy Baynes, senior vice president of clinical development, Merck Research Laboratories. \u201cThis submission to the U.S. FDA is an important milestone as we seek to provide<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,140,141,64,289,56],"class_list":["post-745192","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Submits U.S. New Drug Application for Grazoprevir\/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Submits U.S. New Drug Application for Grazoprevir\/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for grazoprevir\/elbasvir (100mg\/50mg), an investigational once-daily, single tablet combination therapy for the treatment of adult patients with chronic hepatitis C genotypes (GT) 1, 4 or 6 infection. Within 60 days of submission, the FDA will determine whether it will accept for review Merck&#039;s application as filed. The company plans to submit additional license applications in the European Union and other markets by the end of 2015. \u201cMerck&#039;s submission is based on evidence from our wide-ranging clinical program assessing the efficacy and tolerability profile of grazoprevir\/elbasvir in populations with chronic hepatitis C,\u201d said Dr. Roy Baynes, senior vice president of clinical development, Merck Research Laboratories. \u201cThis submission to the U.S. FDA is an important milestone as we seek to provide\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\\\/\",\"name\":\"Merck Submits U.S. New Drug Application for Grazoprevir\\\/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-05-28T15:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Submits U.S. New Drug Application for Grazoprevir\\\/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Submits U.S. New Drug Application for Grazoprevir\/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\/","og_locale":"en_US","og_type":"article","og_title":"Merck Submits U.S. New Drug Application for Grazoprevir\/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for grazoprevir\/elbasvir (100mg\/50mg), an investigational once-daily, single tablet combination therapy for the treatment of adult patients with chronic hepatitis C genotypes (GT) 1, 4 or 6 infection. Within 60 days of submission, the FDA will determine whether it will accept for review Merck's application as filed. The company plans to submit additional license applications in the European Union and other markets by the end of 2015. \u201cMerck's submission is based on evidence from our wide-ranging clinical program assessing the efficacy and tolerability profile of grazoprevir\/elbasvir in populations with chronic hepatitis C,\u201d said Dr. Roy Baynes, senior vice president of clinical development, Merck Research Laboratories. \u201cThis submission to the U.S. FDA is an important milestone as we seek to provide","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:11+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\/","name":"Merck Submits U.S. New Drug Application for Grazoprevir\/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-05-28T15:30:00+00:00","dateModified":"2025-11-07T06:25:11+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-submits-u-s-new-drug-application-for-grazoprevir-elbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Submits U.S. New Drug Application for Grazoprevir\/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"5ce1ded7-7c1f-485f-b67b-75b5d787f923","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745192\/revisions"}],"predecessor-version":[{"id":3674639,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745192\/revisions\/3674639"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745192"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}